Merrimack Pharmaceuticals Profile

USD 0.20  3.66%

Merrimack Pharmaceuticals exotic insider transaction detected

Merrimack Pharmaceuticals insider trading alert for general transaction of stock option (right to buy) by William Sullivan, CFO and Treasurer, on August 31, 2018. This event was filed by Merrimack Pharmaceuticals with SEC on 2012-02-01. Initial filing of beneficial ownership - SEC Form 3. William Sullivan is currently serves as head of fin. and accounting and treasurer of Merrimack Pharmaceuticals [view details]   

Merrimack Pharmaceuticals Summary

Merrimack Pharmaceuticals (MACK) is traded on BATS Exchange in USA. It is located in MASSACHUSETTS U.S.A and employs 72 people. Merrimack Pharmaceuticals is listed under Pharmaceutical Products category by Fama And French industry classification.The company currently falls under 'Micro-Cap' category with current market capitalization of 76.32 M. Merrimack Pharmaceuticals conducts business under Healthcare sector and is part of Biotechnology industry. This company has 13.34 M outstanding shares of which 824.44 K shares are now shorted by private and institutional investors with about 11.04 trading days to cover. Merrimack Pharmac currently holds about 60 M in cash with (104.13 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.5.
Check Merrimack Pharmaceuticals Probability Of Bankruptcy

Ownership Allocation (%)

Merrimack Pharmaceuticals Target Price Odds Analysis

Odds Below 5.67HorizonTargetOdds Above 5.67
61.75%30 days 5.67 37.91%
Based on normal probability distribution, the odds of Merrimack Pharmaceuticals to move above current price in 30 days from now is about 37.91% (This Merrimack Pharmaceuticals probability density function shows the probability of Merrimack Pharmaceuticals Stock to fall within a particular range of prices over 30 days) .

Merrimack Pharmaceuticals Top Holders

Merrimack Pharmaceuticals Income Statement Over Time

Consolidated Income    Earning Before Interest and Taxes EBIT    Net Income    

Merrimack Pharmaceuticals Key Fundamentals

Merrimack Pharmaceuticals Against Markets

Merrimack Pharmaceuticals Current Ratings

Merrimack Pharmaceuticals 30 Days Performance Scores

Risk Adjusted
Performance Score (0 to 100)
Chance of
Financial Distress (0 to 100%)
Equity ratings for Merrimack Pharmaceuticals are calculated dynamically based on Macroaxis scoring framework. Click here to learn more
Merrimack Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on biomarker-defined cancers in the United States. Merrimack Pharmaceuticals, Inc. was incorporated in 1993 and is headquartered in Cambridge, Massachusetts. Merrimack Pharmaceuticals operates under Biotechnology classification in USA and traded on BATS Exchange. It employs 72 people. more
Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
Merrimack Pharmaceuticals SEC Filings
Merrimack Pharmaceuticals SEC Filings
Security & Exchange Commission EDGAR ReportsView All
NameMerrimack Pharmaceuticals
CEORobert MulroyView All
Thematic Classification
Currently Active Investing Idea
Cancer Fighters
  Cancer Fighters
View All
Analyst Consensus
Piotroski F Score
Macroaxis Advice
Healthcare, Biotechnology
InstrumentUSA Stock View All
RegionNorth America
Business AddressOne Kendall Square
Foreign Associate  India
ExchangeBATS Exchange
CIK Number0001274792
Phone617 441 1000
CurrencyUSD - US Dollar
Next Fiscal Year EndDecember 31, 2019
Most Recent QuarterJune 30, 2018
Last Fiscal Year EndDecember 31, 2017
Date Short InterestAugust 15, 2018

Merrimack Pharmaceuticals Directors

Merrimack Pharmaceuticals Corporate Directors

George Demetri Director
Vivian Lee Director
James Quigley Director
Please see also Stocks Correlation. Please also try Portfolio Manager module to state of the art portfolio manager to monitor and improve performance of your invested capital.